Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology; Chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital at Yale-New Haven; Associate Director for Translational Research, Yale Cancer Center; Clinical Research Program Leader, Thoracic Oncology Program, Yale Cancer Center
Lung cancer; Thoracic Oncology; Personalized Cancer Medicine; Clinical Trials for Lung cancer; Tumor profiling; Tumor biomakers
Dr. Herbst is a Professor of Medicine and Pharmacology, Chief of the Medical Oncology and Associate Director for Translational Science at Yale School of Medicine and Yale Cancer Center (YCC). Prior to his appointment at Yale, Herbst was a professor of medicine, chief of the Section of Thoracic Medical Oncology, and the Barnhart Family Distinguished Professor in Targeted Therapies at MD Anderson Cancer Center. His primary mission is the enhanced integration of clinical, laboratory, and research programs to bring new treatments to cancer patients.
Dr. Herbst’s laboratory work is focused on angiogenesis and dual EGFR/VEGFR inhibition in NSCLC and targeting KRAS-activated pathways. This work has been translated from the preclinical to clinical setting in multiple phase II and III studies which he has led. He has led the Phase I development of several of the new generation of targeted agents for NSCLC, including gefitinib, erlotinib, and bevacizumab. He co-led the BATTLE-1 effort at M.D. Anderson Cancer Center and now leads the BATTLE-2 clinical program at Yale. He serves as a Co-Program Leader of the Developmental Therapeutics Program at YCC.
Dr. Herbst is a member of the National Cancer Policy Forum for which he has organized an IOM meeting focused on policy issues in personalized medicine. He is a member of the American Association of Cancer Research (AACR), where he chairs the Tobacco Task Force, as well as the American Society of Clinical Oncology and the Institute of Medicine’s National Cancer Policy Forum. He is a fellow of the American College of Physicians. Dr. Herbst is also a member of the medical advisory committee for the Lung Cancer Research Foundation and chair of the communications committee for the International Association for the Study of Lung Cancer. He has authored more than 200 peer-reviewed papers and has current grant funding for his work from numerous sources including the National Cancer Institute, AACR and multiple charitable foundations.
After earning a B.S. and M.S. from Yale University summa cum laude, he received his medical degree from Cornell University Medical College and earned a Ph.D. in molecular cell biology from the Rockefeller University. Dr. Herbst completed his medical oncology fellowship at Dana Farber Cancer Institute and a medical hematology fellowship at Brigham and Women’s Hospital in Boston, where he additionally received a master’s degree from Harvard University in their clinical investigator training program.
Accepts New Patients? Yes
Patient Type: Adult
Accepts appointments from patients or physicians
A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral ALK/EGFR Inhibitor AP26113
Disease/Condition: Anus; Bladder; Bones and Joints; Brain and Nervous System; Breast - Female; Breast - Male; Cervix Uteri; Colon; Corpus Uteri; Esophagus; Eye and Orbit; Hodgkin's Lymphoma; Ill-Defined Sites; Kidney; Larynx; Lip, Oral Cavity and Pharynx; Liver; Lung; Lung Cancer; Melanoma, skin; Multiple Myeloma; Non-Hodgkin's Lymphoma; Other Digestive Organ; Other Endocrine System; Other Female Genital; Other Male Genital; Other Urinary; Ovary; Pancreas; Prostate; Rectum; Small Intestine; Soft Tissue; Stomach; Thyroid
A Phase I/IIa, First Time in human, open-label dose-escalation study of GSK2636771 in subjects with advanced solid tumors with PTEN deficiency
Disease/Condition: Brain and Nervous System; Breast - Female; Breast - Male; Breast Cancer (ER, PR, and HER2 negative); Colon; Colorectal Cancer; Endometrial Cancer; Gastric Adenocarcinoma; Glioblastoma Multiforme; Head/ Neck Squamous Cell Carcinoma; Lip, Oral Cavity and Pharynx; Lung; Melanoma; Melanoma, skin; Non-Small Cell Lung Cancer (NSCLC); Other Female Genital; Ovarian Cancer; Ovary; Prostate; Prostate Cancer; Rectum; Stomach
A Phase II/III Randomized Trial of Two Doses of MK-3475 (SCH900475) versus Docetaxel in Previously Treated Subjects with Non-Small Cell Lung Cancer
A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab with or without Concurrent Cetuximab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) (CIRB) (SWOG S0819)
Disease/Condition: Lung; Lung Cancer; Non Small Cell Lung Cancer
A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer
Disease/Condition: Lung; Non Small Cell Lung Cancer